National Cancer Institute study provided clues about how cancer cells develop resistance to chemotherapy drug
On Sept. 14, 2008, the National Cancer Institute (NCI) researchers and colleagues have shown that increased expression of…
Phase III clinical trial showed patients treated with arsenic trioxide had better overall survival than patients who received chemotherapy alone
On Jan. 23, 2007, results from a large phase III clinical trial show that adult patients with previously…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Radiology | Therapeutics | Women's Health
NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence
In 2006, the National Cancer Institute (NCI) launched the TAILORx trial to determine whether gene expression patterns in…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Therapeutics | Women's Health
Studies validated a new test can predict risk of breast cancer recurrence in a sizable group of patients
On Dec. 7, 2005, results from several studies presented at the San Antonio Breast Cancer Symposium validated that…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Therapeutics | Women's Health
NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…
NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Nanotechnology | Oncology | Therapeutics
FDA approved albumin-stabilized nanoparticle formulation of paclitaxel for treatment of breast cancer
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
FDA approved Kepivance for severe oral mucositis in cancer patients undergoing bone marrow transplant
On Dec. 15, 2004, Amgen announced that following priority review, the FDA has approved Kepivance(TM) (palifermin), the first…
The National Cancer Institute study determined that a new molecular test can predict the risk of breast cancer recurrence
On Dec. 10, 2004, a National Cancer Institute (NCI) supported study determined that a new molecular test done…
Biotechnology | Disease | FDA | Life Science News | Oncology | Therapeutics
Genentech drug Tarceva (erlotinib) was approved
On Nov. 18, 2004, the U.S. Food and Drug Administration (FDA)Â announced it had approved Genentech’s drug Tarceva…
FDA approved the first antiangiogenic drug for cancer, Avastin
On Feb. 26, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved the first antiangiogenic…
The monoclonal antibody cetuximab (Erbitux) was approved by the FDA for the treatment of metastatic colorectal cancer
On Feb. 1, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Cetuximab, a recombinant…
Biotechnology | Diagnostics | Disease | Life Science News | NIH | Oncology | Radiology | Therapeutics
NCI clinical trial showed reduced intervals between chemotherapy improved survival in women whose breast cancer had spread to lymph nodes
On Dec. 12, 2002, the National Cancer Institute (NCI) announced that a clinical trial had shown that reducing…
FDA approved Amgen’s aranesp for anemia associated with chemotherapy
On Jul. 22, 2002, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved Aranesp (darbepoetin…
NCI scientists identified adult patients with non-Hodgkin’s lymphoma likely to be cured by chemotherapy
On Jun. 19, 2002, National Cancer Institute (NCI) scientists used microarray technology to determine the patterns of genes…
Researchers discovered that the most common form of non-Hodgkin lymphoma is actually two distinct diseases
In 2000, researchers discovered that the most common form of non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma, is…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Oncology | Therapeutics | Women's Health
The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
Brenda Gallie identified the cause of drug-resistant childhood cancer of the retina
In 1996, Dr. Brenda Gallie identified the cause of drug-resistant childhood cancer of the retina, leading to an…
The FDA approved Amgen’s Epogen/Procrit for the treatment of anemia
On Apr. 1, 1993, the FDA approved Amgen’s Epogen/Procrit for the treatment of anemia due to the effects…
Post-operative (adjuvant) radiation therapy and chemotherapy are found to improve survival in rectal cancer
On Mar. 4, 1991, researchers reported that post-operative (adjuvant) radiation therapy and chemotherapy were found to improve survival…
The FDA approved the hormone, called Epogen
On Jun. 1, 1989, the FDA approved Amgen’s Epogen/Procrit for the treatment of anemia associated with chronic renal…
Bristol-Myers’ PARAPLATIN (carboplatin) was approved for the treatment of recurrent ovarian cancer
On Mar. 3, 1989, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers’ PARAPLATIN (carboplatin) for the treatment…
Additive solutions were shown to extend the shelf life of red blood cells to 42 days
In 1983, additive solutions were shown to extend the shelf life of red blood cells (RBC) to 42…
Vincent T DeVita, Jr. became the ninth director of the National Cancer Institute, serving until 1988
On Jul. 9, 1980, Dr. Vincent T. DeVita, Jr. became the ninth director of the National Cancer Institute…
Biology | Chemical | Disease | Life Science History | Neurology | Oncology | Therapeutics
Bristol-Myers introduced CEENU (lomustine), a chemotherapy product for brain cancer and Hodgkins lymphoma
In 1976, Bristol-Myers introduced CEENU (lomustine), a chemotherapy product for brain cancer and Hodgkins lymphoma. Lomustine is an…
Dr. E. Donnall Thomas brought his pioneering work in bone marrow transplantation to the Fred Hutch
In 1975, Dr. E. Donnall Thomas, a pioneer in bone marrow transplantation, secured a permanent treatment home at…
The FDA approved doxorubicin (Adriamycin)
In 1974, the U.S. Food and Drug Administration (FDA) approved doxorubicin (Adriamycin), an antitumor anthracycline antibiotic from Streptomyces…
Jane Wright became the first woman to be elected president of the New York Cancer Society.
In 1971, Jane Wright became the first woman to be elected president of the New York Cancer Society….
The first chemotherapy oncologist joined Swedish Tumor Institute
In 1969, Dr. Ed Webster joined the Swedish Tumor Institute as its first chemotherapy oncologist. The Instutute opened…
St Jude researchers find that chemotherapy is effective against Ewing sarcoma, one of the most frequent malignant bone tumors in children
In 1968, St. Jude researchers find that chemotherapy is effective against Ewing sarcoma, one of the most frequent…